The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism

To assess the effect of oral AZ D0530 at various doses on neuroimaging parameters associated
with various forms of impulsivity mediated through glutamate-dopamine interactions, as
ascertained through functional magnetic resonance imaging. -- --NOTE-- AZD0530 dosage of 50mg
was discontinued by manufacturer. Adjustments were made to account for the removal of the
50mg dosage in all arms of the study.

Inclusion Criteria:

- Clear History of at least 1 parent having a history of alcoholism or no first or
second degree relatives with alcoholism or substance abuse

Exclusion Criteria:

1. Exclusion criteria include: Current diagnosis of DSM-IV-TR Axis I disorder

2. Report of psychotic disorder in a 1º relative

3. Auditory or visual impairment that interferes with test taking

4. History of prenatal exposure to alcohol plus currently meeting criteria for features
of fetal alcohol syndrome

5. Not speaking English fluently or being a non-native English speaker, or being educated
in a primary language other than English >grade 1

6. Mental retardation (Full Scale IQ<70) using 2 WASI subtests for IQ estimate

7. Traumatic brain injury with loss of consciousness > 30 minutes, or concussion in last
30 days

8. Presence or history of any medical/neurologic illness that may affect brain physiology
(e.g., epilepsy, Multiple Sclerosis), including focal brain lesion seen on structural
MRI (all structural scans are read by a licensed radiologist)

9. Current pregnancy (all females will be tested with urine screens on the day of MRI and
prior to each phase of drug treatment)

10. Positive urine screen for the presence of marijuana, cocaine, opiates or breath screen
to detect the presence of alcohol, administered at each lab visit.

11. Inability to comprehend the consent form appropriately

12. Ferromagnetic metal devices, clips or fragments in body (orbital x-ray performed if
needed).

13. Current use (within 30 days of screening) of specific psychoactive medications (e.g.,
typical neuroleptics, narcotic analgesics, antiparkinsonian medications, systemic
corticosteroids, or medications with significant central anticholinergic activity,
etc.). Current use of warfarin.

14. Current use of the following medications (CYP3A4 substrates whose metabolism may be
slowed by AZD0530): carbamazepine, colchicine, cyclosporine, disopyramide,
fluticasone, quinidine, vinblastine, vincristine, nifedipine. Patients taking
sildenafil, tadalafil, and vardenafil will be advised to stop taking these medications
for the duration of the trial. Patients cannot take the following drugs which inhibit
the CYP3A4 isoenzyme: cimetidine, cyclosporine, danazol, fluconazole, grapefruit
juice, HIV protease inhibitors, itraconazole, ketoconazole, macrolides, miconazole,
nefazodone, omeprazole, ritonavir, and verapamil, aromatase inhibitors, docetaxel

15. Neutropenia defined as absolute neutrophils count of <1,500/microliter.

16. Thrombocytopenia defined as platelet count <100x103/microliter.

17. AST, ALT, total bilirubin >1.5 times upper normal; serum creatinine, >2 time upper
normal limit, total bilirubin>1.5 times ULN; Serum creatinine >2.0 times ULN.

18. History of interstitial lung disease.